) Allium ascalonicum > ( 4T1 @ DMBA

(
)
253-261 1393 !" 3
&'
5
4T1
,
(Allium ascalonicum)
- $& '
( )%
DMBA "
) *+
#$ %
&'
!
. /!
MSc.
Ph.D.
Ph.D.
*Ph.D.
-
38156-8-8349
[email protected] :) * +
1393/2/28 :
,-
*
.
1392/6/26 :
!"
* 1+ 2 ,3 4 0 3 * % 3 5& 36 7# * 5 836 5 9
0 /,-
+ ,# -.!% *
& ' () $%
! "# :$
.
C% ' B83 % 3 DE3 . 3; 3+F 1+ 2 ,3 4 * /,364 0 3 * % A* B8# 0
* 3 J 3
5 836 5 9 3 0 /,- 0*
0 3#&
'% . ;
*
/,-
`3+4
4 !
>9
%
0 /,- 0*
X # P< 0/05 U"
J XX4 F# $% ( 8+!
<, + * * 6N,
,3# 5 836 5 9 3 0 3 /,- 0*
8+6+64, ,8+
1 % 8+6+64, ,8+ [ %O % \) /,64
1+R> +# A* B * S+-T * O=
9 P D> %* O+! >&
< J 0/05
+ ,# -.!% *
+-)
1393 !"
+ ,# ' () :(
+$ 1+X^] . ,
& ' () C% 8_+
[ 4 \) G/,64 *
& ' () 4 % 5 _>
* % ' +J P 5%,X)
1+ 2 , 4 G/,64 GDMBA G5 86 5 9
253
0/01) 8?-@ X#%
8+6+64, ,8
-.!% ' () `+4 1+X^] * 1+ 2 , 4
. +J % b 8_+ A 7+7T c, ,# 5 86 5 9
*
,- 0O+#&K> L ,
% ' ; /,64
$% 0% %
0
>
' ; 1+ 2 , 4 8+6+64, ,8+ [ %O % \) G1+ 2 , 4 ' () 5 #O]
.
& ' () % 8 % : %& & '
5& 8+6+64, ,8+ GMTT * ,- 5 E
H-8I# 0 5 #C * ?-@
D C,8 , & * P Q,!, ,# A% ++M
. ; 8 J ?>
-.!% ' () +$ * ;%
?-@ * + ,# -.!% *
% ' ; < =>% /,64
-.!% *
! "# 1 % :* +)
& ' () `+4 * ;
>%, # ' +J 1 % `+ 1
5
(
-
)
#
% Ta
. ,; # * %
G + ,# ' () G 8+6+64, ,8+ :*
3
& ' ()
, +- &
, !
&
...
A 3k+4
3_# +36 34 ' ,3 3 SX
A 3 ! "# .(13-15) ;
* 0 +s.
* MCF-7GHela > 9
-kb
0% ' () IC50
& ' () 8+6+64, ,8
% 8 J %b
$%
5 9 3 1 d ; 5 86 5 9
=X# 5 86 0 5 9
1+ C% 4
*
G
337!% 0 33 /,-33
7-12
0%
3333]+ ' * 5 3333 C% D3333
* (Dimethylbenz(a)anthracene)
,#, 5 +
R3_ #C& A >%,+
,#,
% 8%
33+F 0% 33 * 33; 0 % 33 N 5% 33 %
-DMBA 3333 A
0 'C% 3>%
4T1 !,- '
,3# 5 86 5 9
4 b2N% /,a%
% 9% + > 0 ,# DE . ;
)
,
%S+ %0 L ,
]36b 18 .3; C% D . ; S 8 % ' ; y+b 1!*
C% . 3; S78X# X+#j ,
C
* z N S# 4 ,9
0 3 5,.! 3 3 * ; '
"b ,#,
]6b
. ; ' % / 78>% S 8 % (Balanced
* ' ; z N HBSS C%
5,N 5 4 % e C% D . ; ' *O % 'C
NO
+6 A% {
SE! . %
5C,3 C% 3 1 3Xm -a
% e
C%
,N
/,-
G ; Q,+B 8>
,#, ' > ]+b G
* ;
%
*
5,+6> E , * (chopping) ;
; ' % ,k) 8+! -+# 5 K>
|,-I# DE G >,;
7+b 5 A # 2000rpm *
5 5,.! 3 3 f,3
>,]> DE
_4 L+T# 5&
38+! 3-+# 15 5,.! 3 3 ' 3#& 3
3 . ; 8I *
Dulbecco's (DMEM)
* ' ; S78X#
8_+ A 7+7T < =>% A *
03 P 2
333_4 L+333T# 3338+! 333-+#
3 % FBS (Fetal bovine serum)
' ; 1R] |,-I# C% 8+! -+# 2 1/5 G5 4
38+! 3-+# 5 3 P 2 SN% L+T# h= * ' ; S78X# T25
' % % 3b % CO2 , 3 ,.>% S3N% P 2 DE . ; ' >
* c% 3 % * 5 9
3
5
(
-
)
0
8#
7<>
* 1 3
= % 0 h6+> .#
. C
4 C% . #% ,]> = % 5Q,X+
1 4* 3+ P3 34 3;
5
$,#
,3 * 3 34
3;% F X+#C
_+
5 86 5 9
7!%
% 0% 7- Xm P+ #* &
/ C% D
% A2._# C% 5 86 5 9
S3+kb C% 5 9 3
4 %,#
3# 13 % 8>%OX S3+8# 0 12 *
3 ,4 3kX *
* 3T# O3+> %
c,>
# .;& %
+]+; ' # ),> C% ' B8 % A
O3+> > 3# 0
59
G 5,# , +?> S#%,) C% B-8I# c%,>% L ,
9 C% .(4) ,; #
-]e C% * 5 9
c%,>% C,X
.(5)
,_4 `-@%
o % 0 * % ' 86J
(# 5 +# 1 %
#* 7# = % `e,# 1+-.+ % 8>& * 5 64
> 3# 0 3 3X OJ
3
340 ,9
,; #
.(6) XX4 #
3_X# 3 0 % 3@ p,3(N
>% %
59
% @ 4
<, P *
# 5 _> A ! "#
C% 0 +R_+ S+6> 8 G
> 3# H3-8I# A% 3$% 3 0 3]8# 5 +!
13 % ' ; 8N X; 0
O# C% .
9
%'
+J
5 6>% .(7)
+J 0 ' ()
H3+9 J 836J * q > "N k> e i %,) ,e* < ) ' ()
3>,J 0 3r)%
5%, # 5 +J 1 % -]e C% . ;
# 5& $%
.(8) ,]> ' ;% ( + ,# * C + * + ) Allium
f,36T# (Allium) <,3+!& DXe C% ]F# >,J 4 + ,# ' +J
3(# 5% 3 % 3-]e C%
,_4 C% 0 +6
p%,3N 0% % ' 3+J 13 % . 3 % 83;%
C
C%
J #
% @
8X
>#
G . Q,!, 3] 0 3 tN 3; 0* 3 3$% Ss# 0%' ; 8N X;
',
84
`3+4 G1 %
*v b
'*2) .(9-12)
S3s# 0 3 C A 3k+4 0% %
1393 !"
%
5 # ,_4
5%,3 3# % 5 86 5 9
* /,-T# 5& C% D
3a 100* 3 S# 4 Modification of Eagles Medium
Q 38E+ C% D3 . 3_J
03
3
Salt Soution HBSS Hank's ) 338+! 33-+# 10 0* 33
' % % bS 8 %0 8
# 5 >C 5 +#
4 c,> C% Gg #
28 % i #
*
,#, ?>
-N% 0
1+ C% . ,; #
G 59
% =# 0 #,X+
# % b59
* 5%O+>, 0 ,
5%,+ G<Cj
3a 70 S.!% C% ' B8 % U _ ST# * ' ; ' +;% x+
,3#
.
+3; G % 3@ h3 Q G 3.+8>Q A% 3++M 3 5%, # 5&
3A
,8+836>% C%
/
%,# `-@% * (2*1) ;
S3#%,) .(3) 3 % he 3F#
> 3# 0 3
,83
0 0 ''
13 % 3 5 28k# #& 5 , j . ,]> ' ;% "+T# 0 ,84
! "# ,# 4T1 !,- '
*
4
f,36T# > 36>% d#%,e ' ]) A2._# C% . ' %,] 5 9
+ ,# -.!% *
A% $% + ,# -.!%
% A* B8# !,- '
0* 3 +3 ,# -.!% *
.
"%
% ' ; < =>% L-929
B-8I# P+64, ,8
.(16)
,e,#
!,- 0 ' 0*
* 3X4 3# / 3])% %
! "#
>,J
A% $%
# 5 _> F>& o 8> .
!1 & .2 3
,B!, ,> J %
# 5& ' %,> N h 0
3 & ' () P+64, ,8
* 3 & ' 3()
- *
'
p%,N Gu8>% +64% u8>& S+6> 8
% 8 J % b ! "# ,# 4
34 3
3# 5 _> 5&
+]+;
254
, !
&
...
100 * 0/1 C* 3 3> N 24 3+- 3 ' +k6m 0 /,- . ;
* 0/04 * 1+ 2 ,3 4 * /,64 `+
) 3 48 A 3# 3
MTT * ,- 5 E
03
3
0% 3
-.!% *
& ' () 0%
6N,
< J 0/03
C*
% , & h + * * 86 0Q,!, ,#
:5'
! "#
J < =>% (Olympus, Japan)
8 & 9 ' :':2
.
C% ' B83 %
/,- P Q,!, ,# * D C,8 , & A% ++M
! "#
. 3; 3
3
13 %
-'1'6 ' 7
<, + * *
6N,
>
,- 0O+#&K>
C% !,-3 g # .>& t+I_ * !,- g # c,b*
0O+#&K> * DX ,- ‚,. * .+# C% G ;
0 3 /,-3 0O3+#&K3> 1 %
4
,a
G >,; # '
Fe
# D C,8 , & c,>
. ; ' B8 % 33285
N%,X.
5 3; h4% 38# " %* D C,8 , &
6N,
& K> A ,a
,I8
0 /,-
f 3I8>% + ,# ' +J h! 0
' R83
P3
3 * |,3-I# S 83 % 'O+>, f•& 1
5 A 3# 3 7+b
O3
Tukey 5,#C& G
.
* 5C* 5& C% C +> ,# % 7# G' B8 %
X#
#% &
5Ch
a Fe
% O
JS
' R8
8+! -+# P h=
_4 L+T#
' ; ]+ 0 /,-
GQ,B 8> C% D * % e 1+6E
% 3b , ,.>%
7+b
0% * ; 0 % R>
& ' () G1+ 2 , 4G/,64
h3= 3 S3a
/,- % 8 % G + ,#
'C
_4 L+T#
!,-
!,-3 5,+6> E , C% 8+!* .+# 300 % 7#
7+b 2 A # * |,-I# ,- 5 E
8#,8 3 ,] <j 3 ' 3# * ' 3>C 0 3 /,' # 0 /,- G * 1 %
9P
J 7- %
G + ,#
T 5 ;
* ' 3#& P3_N ,3 A ,3a 3
3-.!% *
D> %* O+! >& SPSS 0 #& %O % < > C% ' B8 % :* 2 ; 1 2
P <0/05 * 3; < =>% ' % 0*
* 14000 L % ;
86
%,N 5 _>
1 k6>
C% ' B83 % 3 * 3; % 3e 3 * d 3# * ' ; Q,B 8>
DE * +
.%
b f+ &
' 3() S3# 4 0 3+J ' 3() C% D . ; ' O]
836 C A 3b [=X 0% .(18)
<, + *
G + ,#
3mC + DE . ; % e 5& e N 8 , *
+k9
& | 7> A ,a
J 3+4* m * _@ ` I O+>
mC + C% < J 100 *
S3# 4 5 3; ! C% D * ' #& < > ' # A ,a
0O+#&K> . ,
% h3 2 ,8+
_4 L+T# 8+! -+#
'C
3 & ' 3() 3+F 0% 3 .(17) _J ~+-M ' () * % e /2
f,
_# S b 5 _N
.
* ' ,]> , % 5& G5 ; P_N * + ,# +F C%
* h?X3# 3+@ ,39 3 G 836 5 3; 3 "b 3 "b * 1+ #* 4
%,N '
/
3 * L+T# ) 24 ; J C% D . ;
. _J ' *O % P 2
3k #
0 0 ''
5& C% D3 * ' 3; 8-+ DE . ,; # 0 +J ' () } % 0 #
DX ,- ‚,. * .+# L , ' >C * ' # /,- 1+ O ] 0%
.
4
) 3 24 A 3# 0% (5 1 k6> ) a 95 /,> %
- #
1+ #* 4 0O+#&K> .( ; f I8>% 0Q,!, ,#
'% ]
5 * 3+-I P3 2
e, ) ; ]+
) 3 48 5 3#C A # *
!1 & .2 3
< J* .+#
8+!
0 5,#C& 0 #& o 8>
0% 3
36N,
8+! -+#
'
'*2) . ; '
. ;' %
%
. ; 5 + a A ,a *
& K>
' ; ]+ 0 /,-
C% 0* 6#
G,- 5 E
86 C A b
0
{,B> -)
0% ,- 5 E
*
dimethylthiazol-2-yl]-2,5 diphenyl -4,5]-3)
13 %
3>%,8 4 * % * ' () C% 8?-@ 18
* 48 3]+ ' * G 3
[ 4 a 50 %
/,-
86 C
3 3e, 3 3 * % * ' () C% C* 0 ' * T# * 8)
G 3 [ 3#C& < =>% C%
*
.(1 /* e) ; f I8>%
& ' () 4 % 5 _> 5,#C& 1 % C% ' #&
72
_# A ! "#
0 '%
3+Jh3_m [ 34 `3e,# 1+ 2 , 4 * /,64 G + ,# -.!%
. > ; >9
0 /,-
86 C
. ; ' B8 % O+> MTT assay(tetrazolium bromide
0+ %
,?X# [ *ƒ 1 %
>%,
* C%
>%, 0 X4,8+#
C >Q* +
A X+64, h O>&
/,-T# 3> * >%,3@ % 0 3 ,- 3 % /*C 3+ S+8# 0
3+-
) 3 24 A #
96 3+- H4
>9
*
C K>
0 /,- . % 5%C # ,
/,- 1 % 5 +k6m C% D * _4 > N 96
* 3 & ' 3() G1+ 2 , 4 G/,64 C% ,4 # 0
?-@
>N
10 ) 3 72 * 48 0 3 5 3#C C% D3 * 3]+ +3 ,# -.!%
3
3_4 L+3T# C% 38+!* .+# 1000%C% 3 MTT 8+!* .+#
0 3 ,3- DE3
; ,.>%
)
4A # *
L33 , 5& f 33e * S33 DMSO
S33a
(enzyme-linked
% P m
5%C 33# ,
immunosorbent) ELISA reader
0 +J'C% >% 8#,> > 505 z,# /,9 (Model Bio-Rad 680)
255
1393 !"
3
5
(
-
)
, !
&
...
5 #Ch 0
'
!1 & .2 3
?-@ * + ,# -.!% * & ' () G1+ 2 , 4 G/,64 H-8I# 0
( 8+!
( 8+! -+#
0 0 ''
/
& ' () H-8I# 0
?-@
< J 0/05 G0/04 G0/03 G0/02 G0/01) -.!% ' () H-8I# 0
?-@
< J* .+# 500 G400 G300 G200 G100) 1+ 2 , 4 H-8I# 0
?-@
(5=500+0/05 ) G(4=400+0/04 ) G(3=300+0/03 ),(2=200+0/02 ) G(1=100+0/01) :' () * 1+ 2 , 4 `+4
( 8+! -+#
< J* .+# 10 G1 G0 G0/01 G0/001) :/,64 H-8I# 0
?-@
(5=10+0/05 ) G(4=1+0/04 ) G(3=0/1+0/03 ) G(2=0/01+0/02 ) G(1=0/001+0/01) :' () * /,64 `+4
\3) /,364 * +3 ,# 3 & ' 3() 5 #Ch
' () 5 #Ch
+$
* ' ; /,64
3 3 ' () 1 % 5 #Ch
+$
8+6+64, ,8
+$ G1+ 2 , 4
' 3; 1+ 2 ,3 4 8+36+64, ,8
4 !
5 #Ch A ,a % 1+ 2 , 4 * /,64 0
[ 4
+ ,# -.!% *
[ %O % \) G1+ 2 , 4
.
%
34 3; '
4T1 !,- '
1393 !"
3
5
(
8) 48 ]+ :4-1
-
)
$% /,- 0*
' () 1 % * ,; # /,- 1 % 8_+ F# \) C*
J # >9
0 /,- 0*
?-@ ]+ C% D 5 86 5 9
7!% 0 /,- * 4T1 !,- ' 86 C
-.!% * & 0 ' () 1+ 2 , 4 * /,64 5 #Ch +$ G1+ 2 , 4G/,64
7!% 0 /,/,- A + a 1+R> +# 0 6 7# :2-1
+ ,# & ' () ]+ 4T1 ' 0 /,- * DMBA
& ' ()
A ,3a 3 /,364 0* % 3 + ,# -.!% ' () 5 #Ch
.
G -.!% * & ' () H-8I# 0
3_# * (1 % ,3]>) ' %
•
•
•
•
•
•
0 5,#C&
72 * 48 0 3 ]+ A ,3a 3 +3 ,# ' +J -.!% *
&
.
?-@ :1/* e
< J 0/05 G0/04 G0/03 G0/02 G0/01) + ,#
( 8+!
4
+$
86 %*
+$ [ %O % \)
>%, 1+R> +# 6 7# :1 % ,]>
* DMBA
7!% 0 /,- A +
+ ,# -.!% ' () ]+
4T1 !,- '
/,64
8)
a 1+R> +# 0 6 7# :1-1
4T1 ' 0 /,-
8) 48 ]+ :3-1
256
, !
&
...
DMBA
DMBA
8) 48 ]+ . :5-1
7!% 0 /,-
8) 72 ]+ :8-1
DMBA
7!% 0 /,-
8) 72 ]+ :7-1
DMBA
8) 72 ]+ . :10-1
36N, 3 0O3+#& K3>
[- )
J'
' 3; ]+ 0 /,_#
"b
# 5 _> % H-8I# 0
G * % * ' 3() 3 3]+ C% D
X3 * ,- K3> C% ' B83 %
/ 8X4 '* J
6 7#
)
7!% 0 /,-
.
8) 72 ]+ :9-1
3 3]+ C%
* Skb /,- G !,- 0Q,!, ,#
% 3b 3
,3# A ,X % ‚,. * .+# L ,
Fe
b
' ()
"b * h4% 8#
* h! 3 A ,3a 3 3 ' 3() 3 3]+ C% Skb /,- . X8 J
]+
D3
8
/,- P Q,!, # A% ++M
48 5 #C A #
86 S.; ++M S# ;
.(2*1 0 S.;) .
%' ;' %
/,- 1 %
_@ G
. > ;
<, + *
* 3> , ' 3; ` I
0
†
; 0 /,-
?-@ ' ; ]+ ) '
O3# b K3> 3
3
m E.
?-@
6 7#
`+ & 0 /,- 5*
]+ C%
h 2 ,8+
PI K>
/,- 1 % 86 % ! * 8 '% (' () H-8I#
0% % (A G2 * 1 0 3 S.;)
1393 !"
+k9 2# 4 86
0O+#&K> * j 0
3 % , <, 3+ *
257
/
7!% 0 /,-
.(D *
5 3_> C
0 0 ''
DMBA
C G2 * 10 S.;) X
36N,
4
8) 48 ]+ . :6-1
836 * (E * B G2 * 1 0 3 S.3;) 3> , {,3B> S3 b +@ PI
3++M 0 3 86
!1 & .2 3
7!% 0 /,-
4T1 !,- '
A ,3a 3
'
; 0 /,- . > ; 0O+#&K>
X3 ,- K>
5
(
* ' , h!
-
)
] 2 _@
, !
&
...
* 38 3++M 0 3 /,- 86 [- .(40 × ]XJ O )
38+! 3-+# 3 < J * .+#100 ?-@ ' ; ]+ DMBA
0 3 /,- (D G/,64 8+! -+# * J * .+# 0/01 ?-@
0O3+#& K3> * 3 & ' 3() 38+! 3 < 3J 0/04 3?-@ 3 '
'
!1 & .2 3
4
0 0 ''
/
.
) 48 5 #C A # 0% DMBA C% ' B8 %
7!% > 9 0 /,- DX ,- 0O+#& K> :1 S.;
7!% 0 /,- (B G ; >,]>(A . X # 5 _> % ]+ $% (K> O# b 86 ) ' `+ & !,- _@
' ; ]+ DMBA 7!% 0 /,- (C G % , <, + * * 6N, 5 #Ch 0O+#& K> * 1+ 2 , 4
; ]+ DMBA 7!% 0 /,- (E G -.!% ' () 8+! < J 0/03 ?-@ ' ; ]+ DMBA 7!%
. % , <, + * * 6N, 5 #Ch
3_@ * 38 3++M 0 3 /,-3 836 3 [- .(40× ]XJ O ) 4T1 !,- '
) 48 5 #C A # 0% D C,8 , & * P Q,!, ,# A% ++M
:2 S.;
G1+ 2 ,3 4 38+! 3-+# 3 < J * .+# 100 ?-@ ' ; ]+ 4T1 0 /,- (B G ; >,]> (A . X # 5 _> % ]+ $% (K> O# b 86 ) ' `+ & !,4T1 0 3 /,-3 3]+ (E G & ' () 8+! < J 0/04 ?-@ 4T1 0 /,- ]+ (D G/,64 8+! -+# < J* .+# 0/1 ?-@ ' ; ]+ 4T1 0 /,- (C
. + ,# -.!% ' () 8+! < J 0/03 ?-@
1393 !"
3
5
(
-
)
258
, !
&
...
1+X^] * DNA 5 ; >
8G3CE 45 ;/
0% 3 83_+ A 3 ! "# 3 C 3+> / 3 3
3?> 3 0 * 3
>9
+ ,# $%
X;
.
3 836 %* A ,3a 3 /,364
3
!*
/,364
% >9
34 ; tI_#
0 /,- 0*
8+36+64, ,8
< 3=>% y3+7T * 3
#
! "# 1 %
0 F# $% 0% %
G ) 3 72
! "# o 8>
48 C% ]+ [ %O %
28N% .
#[ 4
13333.]# G(21) PC-Zd * PC-Sh GOVG-1 GHT-29 GU373
,3- 5 E
?-@ * /,- c,>
28N% S+!
0O+#& K> 5,#C& * C% ' #&
%
o 8> Š %
/,364 5 #Ch ' B8 % 4 ; tI_# MTT =X K> *
% ' ; /,64
8+6+64, ,8
[ 4 \) G & ' () *
3-.!% ' 3() * /,3364 5 3#O]
+$ 3
,33#
.
133 %
-N% # y 9 C% % /*C% ,4,> * /,64
+!
; 1 % X .(27) X4 # F#
1+33X^] . 3 6>% ' 3 () 133 %
1+833 ˆ,4
3# [ 34 O3+> 1+ 2 ,3 4 8+6+64, ,8
A% 3$% G -.!%*
.
X # U"
/,64
+?>
*%
5& [X4 h
. ;
+3 ,# ' 3()
>9
' # 0 /,-
%
5*
3+!
,e,#
* >9
+]+;
0 /,-
0 /,-
]+ / k>
)
9 C%
48 5 #C A #
[ %O % 1+X^] * 86 5 ; % f k *
G5&
0 3 /,-3
836 C
>%, +Jh_m [ 4 `e,# 1+ 2 , 4
83 % P
5,#C& *
C% ' #&
‡ 8> . > ; > 9
. > ,]> + % R . * ' ,
P+364, ,8
A% 3$%
"%
1 % C% [+ 4
8 J A ,a + ,# -.!% *
,-3
836 C
3 /,364
3>%, [ 34
A k+4 1 %
>%, O+>
34 ' 3; tI3_# . >%' % 5 _> %
* (19) C,38+# h+367 G2/M - #
3 /,-3 g 3# `3e,# (20) 5&
U373 !,-3 0 3 '
>9
%
0 /
DNA 6 ,>* Hb,
3 ) Aj 3( % y3 9 C% DNA
1+3
! "#
& 0' () G1+ 2 , 4 G/,64
/ ( % 1+ 2 , 4
4S]) SN% * 0% 8;
3 38 J A ,3a 0
. ,; #
333R] (24) SK-OV-3 * OVCAR-3
8+3336+64, ,8
. >%' % 5 _> % 1+ 2 , 4 * /,64 0j
* 0 3+s.
3 A% 3$% 3 3" %
!,- 0 ' 0*
3-) 3>%, 3# 4 ; '
. ; ' ; ]+ 0 /,- S.; ++M `e,# 4 ;
_# O+>
!,-
3 ! "#
5,3X4 3 34
+ ,# -.!% *
& ' () P+64, ,8
3# 5 _> 8 J A ,a L-929 * Hela,MCF-7 > 9
3
/,- c,>
86 H-8I# !,- 0 ' 0*
' () 1 % 4
0% ' () IC50 * X4 # / ])% B-8I# P+64, ,8
.(16)
3?> C% 34 3 % ' % 5 3_> +3 ,# 0' 3()
1+ 6+!& - 1+6+!& 0 J,J `+4 * 0% %
4 ;
1+3]
# 1+>,
+]+; O=
+]+; A k+4
* 1+8 ˆ,4 S+kb C%
,3e* C% 3; > O3+> 5& > 9 3
+ˆ,>*2 G2*1
3 p%,N C% _I
.(25) ;
3#% G 36+> 13;*
,N
A% $%
% A* B8# !,- '
# C +> ,# 1+ 2 , 4 *
S.3; ++M S+kb C% P Q,!, ,# A% ++M
3] O>&
% 1+ 2 , 4
3Fe 0 83_+ A 3_ #C& < =>% ,e* 1 %
3 5 3; +$ c,3> * 3 ' 3() C% P3 3
>%,
0 /,-
& ' () 4 % 5 _> MTT * ,- 5 E
& ' () * 1+ 2 , 4 5 #Ch
# [ %O % 0 %
A 3k+4 O+! 3>&
>9
* /,364 G 3-.!% *
+]
G ) 33 72 33 48 C% 33]+ [ %O33 % 33 334 33; tI33_#
P+364, ,8
5,#C& * C% ' B8 %
(23) SKOV3G U937 (22)SC-M1 G NUGC-3 (21)Zd
9
' B83 % * 3
86 C
.
PC-G PC-ShG HeLa, MCF- 7, OVG-1,HT-29 GA549 G
,3e* C% 3; > % +3 ,# 3 & ' 3() L3 , /,364
3
/
% ' ,k> 1+Xm1 %
P
3$% [ 4 S j C% . 5%,8
0 0 ''
34 ! 3
1+83 ˆ,4 3+ˆ,>*2 34 3; ' % 5 3_> 3
!,- S.+
4
?-@
GA549 G HeLa GMCF-7 > 9 3 0 3 /,-33 0* 3 ' 3;
. ; /,64 0
!1 & .2 3
> G 86
.(26) ,; # 9 *
0 /,- 0*
'
# A k+4
+ ,# 0 F# h6+> .# 4 Xm
,3e,# 1+83 ˆ,4 4
% ' % 5 _> A ! "# N o 8>
* p53 0 37!% [ %O3 % y3 9 C% % ,3N 0 +s.
A% $% G5&
/ 3])% Bcl-2 * Survivin 0C,38 , & 8>& 0 1+‰ * [ 4
P T \)
+ ,#
,e,# 1+6+!& 1+X^] * (16) X4 #
5 3; h4% 38# G !,-3 S.+3 Hb, GP+ ,8 , & h6e S+._
259
1393 !"
3
5
(
-
)
, !
A 3k+4
&
...
3?> C% 34
% ' % 5 _> + ,# 0' ()
1+3]
+]+;
3# 3 1+>, 3 * 1+83 ˆ,4 S+kb C%
,3e* C% 3; > O3+> 5& > 9 3
+3 ,# 0 3F# h36+> .# 34 3Xm
+ˆ,>*2
A% $% G5&
0 0 ''
37!% 0 /,- * 4T1 C% ' B8 %
/
0 /,-
+$ G1+ 2 , 4G/,64 G -.!%
PI -.!% *
836 % 3! * 38 '% (' () H-8I# 0
,e,# 1+8 ˆ,4 4
& 0 ' ()
?-@ ' ; ]+ )
3; 0 3 /,-3 . > 3; 0O+#&K> O# b K>
/,- 1 %
0C,338 , & 3 8>& 0 3 1+‰ * 3 [ 34 * p53 0 3 7!% [ %O33 %
K3>
1+36+!& 1+3X^] * (16) 3X4 3# / ])% Bcl-2 * Survivin
1 0 S.;) > , {,B> S b +@ PI % , <, + *
H3b, GP+ ,8 , & h6e S+._ P T \)
3 0O3+#& K3>
+ ,#
,e,#
[- )
/
3X
0* 3 +3 ,# 3$%
3 X; 0% 3 83_+ A 3 ! "# 3 C 3+>
.
13 % 34 3
# ?> 0 *
>9
0 /,-
86 H-8I# !,- 0 ' 0*
IC50 * X4 # / ])%
=X3 K> * ,- 5 E
' ()
B-8I# P+64, ,8
8+6+64, ,8
' ,3k> 1+3Xm13 % 3-.!% ' () * /,64 5 #O]
3# 5 3_> %
' ; ]+ DMBA
[ 4 \)
+$
,#
< 38T# 3>* # ! 3# 0 3
] C% ! 7# 1+B!,# -+ *1
* .3_ [ *ƒ3 13 % y7T
q% % ' R_>% 0 * X * [ *ƒ
DMBA
%
. X ]> # 0 %OR E
1. Ferlay J, Bray F, Pisane P, Parkin DM. Cancer
incidence,
mortality
and
prevalence
worldwide,Lyon: Globocan IARC. 2000. In Press.
2. Albano JD, Ward E, Jemal A, Anderson R, et al.
Cancer mortality in the United States by education
level and race. J Natl Cancer Inst. 2007; 99(18):
1384-94.
3. Li Ci, Uribe DJ, Daling JR. Clinical characteristic
of different histologic types of breast cancer.Br J
Cancer. 2005; 93(9): 1046-52.
-
)
(K> O# b 86 ) '
7!% 0 /,- (B G
86
]XJ O )
`+ & !,; >,]>(A . X
< J * .+#100
?-@
7!% 0 /,- (D G/,64
37!% 0 /,- (E G -.!% ' () 8+!
1+ 2 ,3 4 * /,364 G -.!% *
836 C
5,#C& *
< J 0/03
& ' () 4 % 5 _> MTT
3>%, 3+Jh_m [ 4 `e,#
C% ' #&
‡ 8> . > ;
. > ,]> + % R .
3 1+ 2 ,3 4 * (19) C,38+# h+367 G2/M - #
SN% * 0% 8; 1+
03
(
[- .(40 ×
86
3?-@ 3 ' 3; ]+ DMBA
* ' ,3 83 % P3
5
++M 0
38+! 3-+# 3 * 3J * .+# 0/01 ?-@ ' ; ]+ DMBA
> 9 3 0 3 /,-3
3
8
D: DMBA * C G2 * 10 S.;)
++M 0 /,]+ $%
]+
6N,
37!% 0 3 /,-3 (C G 3 % , <, 3+ * * 6N, 5 #Ch
.
1393 !"
"b * h4% 8# A ,a
3# 5 3_> % H3-8I# 0
) 48 5 #C A # 0%
0O+#& K> 5,#C& * C% ' #&
% ' ; /,64
"b
0O3+#& K> * 1+ 2 , 4 8+! -+#
G 3 & ' 3() * /,64 5 #Ch ' B8 % 4 ; tI_# MTT
34 ! 3
_#
X ,-
86 * .(E * B G2 *
' ; ]+ 0 /,-
J'
3_@ * 8
# 5 _> 8 J A ,a L-929 * Hela,MCF-7
A% 3$% /,-3 c,>
o 38> Š 3 %
1+X^]
] 2 _@ 0% % (A G2 * 1 0 S.;)
* ' , h!
* DNA 5 3; > 3 > G 836 5 3; h4% 38# G !,-3 S.+
.(26) ,; # 9 * 8 G 3 C E 4 5 ; /
.
]+ C% D 5 86 5 9
' 3 `+3 & 0 3 /,-3 5*
,N
7!% > 9
?-@
1+ 2 ,3 4 * /,64 5 #O]
# A k+4
3 % ' % 5 _> A ! "# N o 8> #% G 6+> 1;*
y3 9 C% % ,N 0 +s.
4
* 3 & ' 3() H-8I# 0
3 p%,N C% _I
.(25) ;
!1 & .2 3
+]+;
G2*1 1+ 36+!& - 1+36+!& 0 J,3J `+4 * 0% %
34 3;
'
) Aj ( % y 9 C% DNA
. ,; # /,- g # `e,# (20) 5&
HeLa, MCF- GA549 GU373 !,- 0 '
DNA
/(%
4S])
8 J A ,a
SC- GNUGC-3 (21) PC-ZdG PC-ShG7, OVG-1,HT-29
SK-OV- * OVCAR-3 (23) SKOV3 G U937 (22) M1
% 1+ 2 ,3 4 * /,64 0j
8+6+64, ,8
R] (24) 3
. >%' % 5 _>
3
# 5 _> 8 J A ,a L-929 * Hela, MCF-7 > 9
/,- c,>
86 H-8I# !,- 0 ' 0*
' () 1 % 4
3 O= IC50 * 3X4 3# / 3])% 3B-8I# P+64, ,8
A% $%
260
, !
&
4.Fruebauf JP, Bosanquet AG. In vitro determination
of drug response: a discussion of clinical
applications. principle and practice of oncology.
1993; 7: 25-32.
5.Gerrero MR, et al. Recent advances in breast
cancer biology. Curr Opin Oncol. 2001; 13(6): 4159.
6. Alvaro MA, Edith AP. Treatment options for
breast cancer resistant to anthracycline and
taxane. Mayo Clin Proc. Jun. 2009; 84(6): 533–545.
7.Adlercreutz H. Western diet and western diseases:
some hormonal and biochemical mechanisms and
associations.Scandinavian J Clin Lab Invest. 1990;
50 (S201): 3-23.
8. Fan TP, Yeh JC, Leung KW, Yue PYK, et al.
Angiogenesis:from plants to blood vessels. Trends
Pharmacol Sci. 2006; 27(6): 297-309.
9. Adeniyi BA, Anyiam FM. In vitro antiHelicobacter pylori potential of methanol extract of
Allium ascalonicum Linn. (Liliaceae) leaf:
susceptibility and effect on urease activity. J
Phytother Res. 2002; 18(5): 358-361.
10. Leelarungrayub N, Rattanapanone V, Chanarat
N, Gebicki J. Quantitative evaluation of the
antioxidant properties of garlic and shallot
preparations. J Nutrition. 2006; 22(3): 266-274.
11. Owoyele BV, Alabi OT, Adebayo JO, Soladoyea
AO, et al. Haematological evaluation of ethanolic
extract of Allium ascalonicum in male albino rats. J
Fitoterapia. 2004; 75: 322-326.
12. Wang HX, Ng TB. Ascalin, a new anti-fungal
peptide with human immunodeficiency virus type 1
reverse transcriptase-inhibiting activity from shallot
bulbs. J Peptides. 2002; 23(6): 1025-1029.
13. Bianchini F, Vainio H. Allium vegetables and
organosulfur compounds: do they help prevent
cancer? J Environ Health Persp.2001; 109(9): 893902.
14. Fattorusso E, Iorizzi M, Lanzotti V, TaglialatelaScafati O. Chemical composition of shallot (Allium
ascalonicum Hort.). J Agr Food Chem. 2002;
50(20): 5686 -5690.
15.Mubarak AM, Kulatilleke CP. Sulfur constituents
of need seed volatiles: a revision. J
Phytochemistry.1990; 29: 3351-3352.
16. Ghodrati Azadi H, Riazi GH, Ghaffari SM,
Ahmadian SH, et al. Effects of Allium hirtifolium
(Iranian shallot) and its allicin on microtubule and
cancer cell lines. African Journal of Biotechnology.
2002; 8 (19), 5030-5037.
261
...
'
!1 & .2 3
4
0 0 ''
/
.
17. Mohammadi Motlagh HR, et al. AntiAngiogenic Effect of Aqueous Extract of Shallot
(Allium ascalonicum) Bulbs in Rat Aorta Ring
Model. Yakhteh Medical Journal. 2009; 11(2): 190195.
18. Trakranrungsie A. Chatchawanchonteera,W.
Khunkitti.
Ethnoveterinary
study
for
antidermatophytic activity of Piper betle,Alpinia
galanga and Allium ascalonicum extracts in vitro.
Research in Veterinary Science. 2008; 84(1): 80–84.
19.
20. Lee CS1, Kim YJ, Jang ER, Myung SC, et al.
Akt inhibitor enhances apoptotic effect of
carboplatin on human epithelial ovarian carcinoma
cell lines. Eur J Pharmacol. Apr. 2010; 25; 632(13):7-13.
21. Liebmann JE, Cook JA, Lipschultz C, Teague
D, et al. “ Cytotoxic studies of Paxlitaxel (Taxol) in
human tumor cell lines”. British Journal of Cancer.
1993; 68(6): 1104-1109 .
22. Chang YF, Li LL, Wu C, Liu T, et al. Paclitaxel
induced apoptosis in human gastric carcinoma cell
lines. Cancer.1996; 77(1): 8-14.
23. Ofir R, Seidman R, Rabinski T, Kurp M, et
al.Taxol-induced apoptosis in human SKOV3
ovarian and MCF7 breast carcinoma cells is caspase3 and caspase-9 independent. Cell Death and
Differentiation. 2002; 9(6): 636-642.
24. Günther B, Henri B, Nick G, Christian L, et al.
Carboplatin derivatives with superior antitumor
activity compared to the parent compound .
Inorganica Chimica Acta. 2004; 357(15): 4452–
4466.
25. Fattorusso E, Iorizzi
M, Lanzotti V,
Taglialatela-Scafati O. Chemical composition of
shallot (Allium ascalonicum L.). J. Agric. Food
Chem. 2002; 50 (12236699): 5686-5690.
26. Oommen S, John Anto R, Srinivas G,
Karunagaran D. Allicin (from garlic) induces
caspase-mediated apoptosis in cancer cells.
European Journal of Pharmacology. 2004; 485(1-3):
97–103.
27. Samuel T, et al. The Flavonoid Quercetin
Transiently Inhibits the Activity of Taxol and
Nocodazole Through Interference With the Cell
Cycle. Nutrition and Cancer. 2010; 62(8): 1025–
1035.
1393 !"
3
5
(
-
)
Journal of Cell & Tissue (JCT)
Autumn 2014; 5(3):253-261
Original Article
Cytotoxicity Effect of Aqueous and Alcoholic Total Extract of Shallot
(Allium ascalonicum) on Cancer Cells Derived from Mammary Tumors in
Rat and Cell Line (4T1) in Mouse, and Comparison with Taxol and
Carboplatin Chemotherapy Drugs
Hamta A, Ph.D. *, Shariatzadeh SMA, Ph.D., Soleimani M, Ph.D., Tajali Ardakani M, MSc.
-Department of Biology, Arak University, Arak 38156-8-8349, Iran
* Email corresponding author: [email protected]
Received: 17 Sep. 2013
Accepted: 18 May. 2014
Abstract
Aim: The present study aimed to investigate the effects of aqueous and alcoholic extracts of shallot on
breast cancer cells compared to carboplatin and taxol treatments.
Material and methods: Different concentrations of drugs taxol and carboplatin and aqueous and
alcoholic extracts of shallots were prepared.
Using Trypan blue and MTT, cytotoxicity on breast cancer cells, in different times and concentrations
were evaluated. Utilized Hoechst and propidum iodide staining morphological changes and possible
apoptosis of cells were determined. The data statistically analyzed using one-way analysis of variance
and the mean level of P <0.05 was considered significant.
Results: The results indicate that shallot alcoholic extract has more inhibitory effects on cancer cells
than aqueous extract at concentration range (0.01 to 0.05 g/L). Also, the simultaneous effect of
shallot’s extract, accompaniment with carboplatin, caused enhancement in cytotoxicity of carboplatin.
On the other hand, accompaniment of aqueous extract with taxol led to reduction of taxol cytotoxicity.
Conclusions: This study showed aqueous and alcoholic extracts of shallots has cytotoxicity effects on
breast cancer cells on rats affected by breast cancer. This plant is a herb which can be used against
breast cancer can be subjects for further research.
Keywords: Cytotoxicity, Extract of shallot, Breast cancer, DMBA, Taxol, Carboplatin
Journal of Cell & Tissue Autumn 2014, 5(3)
348